Evolva Biotech SA Gets $2.5 Million To Cap Series A With $18 Million, Establishes India Operations

Evolva Biotech SA, a developer of small-molecule compounds, said it has raised an additional CHF3 million ($2.5 million) in a final close of its Series A round to cap the round at CHF21.5 million ($18 million).